FDA
approval
· 2024-12-20
FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)
Summary
FDA approved a supplemental application for dapagliflozin and metformin hydrochloride, enabling a fixed-dose combination product for type 2 diabetes mellitus.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
SUPPL AP for DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE)